Quantum dots-based immunofluorescence technology for the quantitative determination of HER2 expression in breast cancer

Biomaterials. 2009 May;30(15):2912-8. doi: 10.1016/j.biomaterials.2009.02.010. Epub 2009 Feb 28.

Abstract

HER2 detection is important for breast cancer (BC) treatment and prognosis, but the detection methods currently used have some disadvantages. Quantum dots (QDs)-based probes provide a potentially important new method for HER2 detection in clinical practice. This potential is examined in this paper. A QDs HER2 probe kit and QDs image acquisition and analysis software were developed and applied to 94 clinical samples of BC. Compared to conventional immunohistochemistry techniques, this method provided a superior accurate and sensitive method for the detection of HER2 in clinical breast cancer diagnosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Breast Neoplasms / genetics*
  • Feasibility Studies
  • Fluorescent Antibody Technique
  • Genes, erbB-2*
  • Humans
  • Quantum Dots*
  • Sensitivity and Specificity